Skip to Content

GS LHF 75 mg (Tafinlar 75 mg)

Generic Name: dabrafenib

Pill with imprint GS LHF 75 mg is Pink, Capsule-shape and has been identified as Tafinlar 75 mg. It is supplied by GlaxoSmithKline.

Tafinlar is used in the treatment of melanoma, metastatic; non-small cell lung cancer; thyroid cancer and belongs to the drug class multikinase inhibitors. There is positive evidence of human fetal risk during pregnancy. Tafinlar 75 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for GS LHF 75 mg

Tafinlar 75 mg GS LHF 75 mg

Tafinlar

Generic Name
dabrafenib
Imprint
GS LHF 75 mg
Strength
75 mg
Color
Pink
Shape
Capsule-shape
Availability
Prescription only
Drug Class
Multikinase inhibitors
Pregnancy Category
D - Positive evidence of risk
CSA Schedule
Not a controlled drug
Labeler / Supplier
GlaxoSmithKline

Labelers / Repackagers

NDC CodeLabeler / Repackager
00173-0847 GlaxoSmithKline
00078-0681 Novartis Pharmaceuticals Corporation

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.